454 related articles for article (PubMed ID: 16641287)
1. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
[TBL] [Abstract][Full Text] [Related]
2. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.
Barchfeld GL; Hessler AL; Chen M; Pizza M; Rappuoli R; Van Nest GA
Vaccine; 1999 Feb; 17(7-8):695-704. PubMed ID: 10067675
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study.
Pan SC; Hsu WT; Lee WS; Wang NC; Chen TJ; Liu MC; Pai HC; Hsu YS; Chang M; Hsieh SM
Vaccine; 2020 Jan; 38(5):1048-1056. PubMed ID: 31812463
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63).
Pine S; Barackman J; Ott G; O'Hagan D
J Control Release; 2002 Dec; 85(1-3):263-70. PubMed ID: 12480330
[TBL] [Abstract][Full Text] [Related]
6. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.
Nicholson KG; Colegate AE; Podda A; Stephenson I; Wood J; Ypma E; Zambon MC
Lancet; 2001 Jun; 357(9272):1937-43. PubMed ID: 11425416
[TBL] [Abstract][Full Text] [Related]
7. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.
Pan SC; Hsieh SM; Lin CF; Hsu YS; Chang M; Chang SC
Vaccine; 2019 Mar; 37(14):1994-2003. PubMed ID: 30837170
[TBL] [Abstract][Full Text] [Related]
9. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
[TBL] [Abstract][Full Text] [Related]
11. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.
Manenti A; Tete SM; Mohn KG; Jul-Larsen Å; Gianchecchi E; Montomoli E; Brokstad KA; Cox RJ
Vaccine; 2017 Jan; 35(1):191-198. PubMed ID: 27789145
[TBL] [Abstract][Full Text] [Related]
14. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
Tamura SI; Kurata T
Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
[TBL] [Abstract][Full Text] [Related]
15. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
16. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
17. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.
Ugozzoli M; Santos G; Donnelly J; O'Hagan DT
J Infect Dis; 2001 Jan; 183(2):351-354. PubMed ID: 11110644
[TBL] [Abstract][Full Text] [Related]
18. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
19. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
[TBL] [Abstract][Full Text] [Related]
20. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine.
Cusi MG; Lomagistro MM; Valassina M; Valensin PE; Glück R
Vaccine; 2000 Jun; 18(25):2838-42. PubMed ID: 10812227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]